Introduction {#s1}
============

Extended-spectrum and plasmidic-AmpC beta-lactamases (ESBL/pAmpC), which cause resistance to extended-spectrum cephalosporins (ESCs), are of considerable concern in veterinary and human medicine. This is because resistance to ESCs and co-resistance to other antimicrobial families (e.g., fluoroquinolones) limits the treatment options for infections with ESBL/pAmpC-producing bacteria. ESCs and fluoroquinolones, also used to treat animals, have been identified as critically important antibiotics in human medicine ([@B1]).

The emergence of ESBL/pAmpC-producing bacteria in animals and the environment is raising serious concerns ([@B2], [@B3]). In particular, the gastrointestinal tract of animals, including domestic pets, may serve as reservoirs of resistant bacteria that can cause opportunistic infections in vulnerable dogs and could be a source of contamination for humans. For example, dogs could possibly transmit ESC-resistant bacteria due to their close contacts with humans, the high consumption of beta-lactams in small animal veterinary practice ([@B4]), and the frequent occurrence of ESBL/pAmpC-producing *Escherichia coli* ([@B5]). Recently, human-related pathogenic strains have been identified in dogs ([@B6]), and the sharing of identical ESBL/pAmpC strains between humans and dogs from the same households has also been demonstrated ([@B7]).

Although ESBL/pAmpC producers can spread clonally ([@B8]), there is evidence that mobile genetic elements carrying antimicrobial resistant genes can be transferred between bacteria, notably from commensal to pathogenic *Enterobacteriaceae* ([@B9]). Many studies have highlighted the existence of different *E. coli* bacteria harboring *bla*~CTX−M~ or *bla*~CMY−2~-carrying plasmids, some being shared between human and animal strains ([@B5]). Such successful plasmids efficiently contribute to the spread of resistance determinants ([@B10]). In addition, the fact that many strains harboring *bla*~CTX−M−1~ or *bla*~CMY−2~ genes are resistant to other antimicrobial classes may also increase the threat. The use of expanded-spectrum cephalosporins and of fluoroquinolones in dogs is known to select ESBL/pAmpC producers in the fecal microbiota ([@B11]--[@B13]).

Over the past 5 years, the presence of ESBL/pAmpC genes in *Enterobacteriaceae* strains from the feces of healthy dogs in Europe has been reported in several studies ([@B5], [@B7], [@B14]--[@B16]). However, information on the clonality of the ESBL/pAmpC isolates and knowledge about the plasmids carrying these ESBL/pAmpC genes is much more limited ([@B5], [@B15], [@B17], [@B18]).

Thus, examination of the occurrence of ESBL/pAmpC bacteria together with plasmids circulating in healthy pets, and their associated co-resistance, is of major importance with respect to the risk of transfer to humans in daily situations of close contact and will also extend understanding of the dissemination and persistence of ESBL and pAmpC beta-lactamase genes.

The present study was designed to assess the prevalence of beta-lactam and quinolone/fluoroquinolone resistance in fecal *Enterobacteriaceae* from dogs in Spain (Madrid) and France (Toulouse), to identify the potential risk factors for the presence of antibiotic resistance, and to characterize the ESC-resistant isolates, the genes coding for and plasmids carrying ESBL/pAmpC resistance in those isolates.

Materials and Methods {#s2}
=====================

Isolation of *Enterobacteriaceae* Strains
-----------------------------------------

Between March 2013 and January 2014, fecal specimens from 269 different dogs presented at two veterinary clinics (158 at the small animal clinics of the veterinary teaching hospital in Toulouse, France and 111 at a veterinary clinic in Madrid, Spain) were sampled. These dogs were being admitted for a preventive health service, vaccination or medical consultation (disease, trauma, etc.). Dogs were included in the study if they had not received any systemic or local antimicrobial during the previous 4 weeks, according to the owner. Animals with diarrhea were not included in the study. Breed, age, weight, diet (commercial, homemade, other), and reason for the visit (preventive, medical) were recorded for each dog. According to EU law (Directive 2010/63/UE), procedures which use animals according to common veterinary practice did not require minister permission and ethics committee opinion. Sampling were performed by veterinarians in veterinary clinics. They consisted in non-invasive samples (rectal swabbing) performed on client-owned animals and were acquired with the written consent from all owners.

Samples were collected by swabbing, immediately suspended in liquid amies preservation medium (Copan eSwabs Amies liquid, Biomerieux), stored at +4°C and analyzed within 24 h after sampling. Ten-fold dilutions were prepared in 0.9% sterile saline. One hundred microliter were inoculated (i) on MacConkey agar not supplemented with antimicrobials to obtain counts of total *Enterobactericeae*; (ii) on MacConkey agar supplemented with amoxicillin (AMX 100 μg/mL) or cefotaxime (CTX 1.5 μg/mL) to obtain counts of penicillin- or cefotaxime-resistant *Enterobacteriaceae*, and (iii) on MacConkey agar supplemented with nalidixic acid (NAL 20 μg/mL) or ciprofloxacin (CIP 2 μg/mL) to obtain counts of quinolones- (Q) or fluoroquinolones- (FQ) resistant *Enterobacteriaceae*. These antibiotic concentrations have been chosen according to the European Committee on Antimicrobial Susceptibility Testing Clinical breakpoint ([www.eucast.org](http://www.eucast.org)) to obtain non-susceptible/resistant *Enterobacteriaceae*.

All batches of media supplemented with antibiotics were tested with positive (resistant) and negative (susceptible) control strains. Total or resistant *Enterobacteriaceae* (cfu/mL) were counted after incubating these MacConkey agar plates for 24 h at 37°C. The limit of detection was 10 cfu/mL of undiluted liquid preservative medium. The prevalence of dogs carrying resistant *Enterobacteriaceae* (%) was estimated. Samples containing at least 10^4^ total *Enterobacteriaceae*/mL were included in the analysis to limit the risk of underestimating the prevalence. Of the 269 fecal swabs collected, 188 (*n* = 90 from Toulouse and *n* = 98 from Madrid) were included in the analysis.

Multivariate logistic regression analyses were performed to identify independent predictors (sampling site, age, weight, diet, and reason for visit) of resistance carriage (prevalence of AMX-R, CTX-R, NAL-R, and CIP-R) among the investigated animals, using Systat v13.1 version. Statistical significance was set at *p* \< 0.05. Comparisons of resistance abundance were done using a chi-square test with the significance level set at 0.05.

Identification and Typing of CTX-Resistant Bacteria
---------------------------------------------------

CTX-resistant colonies of *Enterobacteriaceae* were collected (one colony per animal), and identified by using API 20E galleries (bioMérieux). Non-*Enterobacteriaceae* isolates (mostly *Pseudomonas* spp.) were discarded.

Multilocus sequence typing (MLST) was carried out according to the protocol described on the *E. coli* (<http://mlst.warwick.ac.uk/mlst/dbs/Ecoli>) and *C. freundii* (<https://pubmlst.org/cfreundii>) MLST website.

Antibiotic Susceptibility Testing
---------------------------------

The antibiotic susceptibilities of CTX-R *E. coli* and their transconjugants were determined by disk diffusion method according to CLSI protocols ([@B19]). The following antibiotic disks were used: ampicillin (10 μg), amoxicillin (20 μg) plus clavulanic acid (10 μg), cefoxitin (30 μg), ceftazidime (30 μg), cefotaxime (30 μg), cefepime (30 μg), aztreonam (30 μg), imipenem (10 μg), streptomycin (10 μg), gentamicin (10 μg), kanamycin (30 μg), nalidixic acid (30 μg), ciprofloxacin (5 μg), tetracycline (30 μg), chloramphenicol (30 μg), trimethoprim (5 μg), and sulfonamides (300 μg) (Bio-Rad, Marnes-la-Coquette, France if available or Oxoid, Dardilly, France). The susceptibility breakpoints for all antimicrobials were those recommended by CLSI ([@B20]).

ESBL production was detected by double-disk synergy test on Mueller-Hinton agar between clavulanic acid and ceftazidime, cefotaxime, or cefepime ([@B20], [@B21]). AmpC beta-lactamases detection was based on the inhibitory effect of cloxacillin on AmpC production observed on plates supplemented with 200 mg/L cloxacillin. The control strains used were *E. coli* ATCC 25922, *K. pneumoniae* ATCC 700603, and *K. pneumoniae* CMY-2 from Pr R. Bonnet, France.

Characterization of *bla~*ESBL*/*AmpC*~* Genes
----------------------------------------------

After bacterial DNA extraction with a DNeasy blood and tissue kit (Qiagen, Hilden, Germany), the *bla*~TEM~, *bla*~SHV~, *bla*~CTX−M~, *bla*~CMY−2~, genes were detected by PCR and sequenced using specific previously-described primers ([@B22], [@B23]). Sequences were analyzed by the BLAST Internet services ([www.ncbi.nlm.nih.gov/](http://www.ncbi.nlm.nih.gov/)BLAST).

Transferability of the *bla*ESBL/pAmpC Genes and Plasmid Characterization
-------------------------------------------------------------------------

Plasmids were transferred by conjugation to rifampin-resistant *E. coli* recipient strains. One-milliliter of a LB culture of the ESBL/AmpC-producing donor strain (10^8^ cfu/mL) and one mL of the J0C0J7-rifR4 rifampicin-resistant recipient (10^8^ cfu/mL) strain were added to 3 mL LB broth and incubated for 2 h at 37°C without agitation. Transconjugants were selected on LB agar containing 1.5 μg/mL of cefotaxime and 100 μg/mL of rifampicin. Plasmid DNA from transconjugants was purified and resolved by electrophoresis in 0.7% agarose, as described previously ([@B24]), to confirm that cells carried only one conjugative plasmid.

Plasmid replicon types were determined using the PCR-based replicon typing (PBRT) scheme ([@B25]) and plasmid sequence subtypes by applying plasmid multilocus sequence typing (pMLST) for IncI1 (<http://pubmlst.org/plasmid/>).

Results {#s3}
=======

Prevalence of Resistant *Enterobacteriaceae*
--------------------------------------------

The characteristics of the dog population studied are given in [Table 1](#T1){ref-type="table"}. A total of 188 dogs (90 from Toulouse and 98 from Madrid), with ages ranging from 4 months to 16 years (median age 5 years), and feces containing at least 10^4^ cfu/mL of total *Enterobacteriaceae*, were included in the study. Body weights ranged from 1 to 53 kg (median weight 10 kg), and most of the dogs (73%) were fed with commercial feed. Eighty-four dogs (44.5%) were admitted for medical consultation, mainly in Toulouse (36.2%), most of them for skin disorders, whereas 94 dogs (50.0%) were admitted for preventive consultation, mainly in Madrid (38.8%), the majority being admitted for vaccination.

###### 

Distribution of the predictor variable from dogs in Madrid and Toulouse veterinary clinics.

  **Risk marker**                         **Madrid**   **Toulouse**   **Total**
  ------------------------- ------------- ------------ -------------- -----------
  Reason for consultation   Medical       16 (9)       68 (36)        84 (45)
                            Preventive    73 (39)      21 (11)        94 (50)
                            Unknown       9 (5)        1 (1)          10 (5)
  Diet                      Commercial    76 (40)      61 (32)        137 (73)
                            Home          4 (2)        4 (2)          8 (4)
                            Mixed/other   10 (5)       6 (3)          16 (9)
                            Unknown       8 (4)        19 (10)        27 (14)
  Age (year)                ≤ 5           54 (29)      48 (26)        102 (54)
                            \>5           42 (22)      39 (21)        81 (43)
                            Unknown       2 (1)        3 (2)          5 (3)
  Sex                       Female                     50 (27)        
                            Male                       39 (21)        
                            Unknown       98 (52)      1 (1)          
  Weight (Kg)               \>20          17 (9)       37 (20)        54 (29)
                            \>10--20      13 (7)       16 (9)         29 (15)
                            ≤ 10          66 (35)      33 (18)        99 (53)
                            Unknown       2 (1)        4 (2)          6 (3)

The prevalences of dogs carrying beta-lactam- or Q/FQ-resistant bacteria and its association with predictor (explanatory) variables are shown in [Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}. Regarding the beta-lactam-resistant *Enterobacteriaceae* in feces, approximately 70% of the dogs carried AMX-R and 18% carried CTX-R *Enterobacteriaceae* (19% in Toulouse and 16% in Madrid). Multivariate regression analysis revealed that dogs in Toulouse were more frequently colonized by AMX-R *Enterobacteriaceae* (78%) than those from Madrid (63%; *p* \< 0.01). The reason for consultation, diet, age and weight were not predictors of beta-lactam resistance carriage among animals ([Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}).

###### 

Multivariate logistic regression analysis for predictor variable associated with antibiotic resistance carriage.

  **Predictor variable**                      **Amoxicillin resistance**            **Cefotaxime resistance**           **Nalidixic acid resistance**           **Ciprofloxacin resistance**                                                                 
  ----------------------------- ----- ------- ---------------------------- -------- --------------------------- ------- ------------------------------- ------- ------------------------------ ------- ------- ------- ------------ ------- ------- -------- ------------
  **Site**                                                                                                                                                                                                                                                   
      Toulouse                  90                                                                                                                                                                                                                           
      Madrid                    98    3.635   1.375                        9.606    **\<0.01**                  1.112   0.379                           3.257   0.847                          0.507   0.206   1.250   0.140        0.598   0.206   1.735    0.344
  **Reason for consultation**                                                                                                                                                                                                                                
      Medical                   84                                                                                                                                                                                                                           
      Predictive                94    0.646   0.262                        1.592    0.343                       1.119   0.401                           3.121   0.831                          3.013   1.289   7.046   **\<0.05**   3.370   1.205   9.425    **\<0.05**
  **Diet**                                                                                                                                                                                                                                                   
      Commercial                137                                                                                                                                                                                                                          
      Home                      8     0.395   0.101                        1.547    0.182                       0.759   0.191                           3.013   0.695                          0.682   0.213   2.181   0.519        1.634   0.328   8.132    0.549
      Mixed/other               16    1.315   0.109                        15.865   0.829                       0.000   0.000                           \-      0.999                          0.660   0.094   4.636   0.676        2.996   0.315   28.459   0.339
  **Age**                       183   0.973   0.891                        1.062    0.536                       0.944   0.842                           1.058   0.324                          0.987   0.904   1.077   0.768        0.950   0.855   1.056    0.345
  **Weight**                    182   1.009   0.974                        1.046    0.615                       1.022   0.983                           1.062   0.283                          1.048   1.013   1.084   **\<0.01**   1.021   0.984   1.060    0.265

*Multivariate logistic regression analyses were performed to identify independent predictors (sampling site, age, weight, diet, and reason for visit) of antibiotic resistance carriage among the investigated animals. Statistical significance was set at p \< 0.05 and is indicated in bold*.

![Prevalence of *Enterobacteriaceae* resistant to amoxicillin (AMX), cefotaxime (CTX), nalidixic acid (NAL), and ciprofloxacin (CIP) in the population of 188 dogs without recent antimicrobial treatment according to the predictor variable. Antibiotic resistance according to site of sampling (Madrid vs. Toulouse) **(A)**, the reason for consultation (Medical vs. preventive) **(B)**, the type of diet **(C)**, dog weight **(D)**, and dog age **(E)**. Possible associations between sampling site, age, weight, diet, reason for visit, and carriage of antibiotic resistance were analyzed by logistic regression models. Asterisks indicate a significant difference, \*\**p* \< 0.01 and \**p* \< 0.05. S, susceptible; R, resistant.](fvets-06-00279-g0001){#F1}

Regarding quinolone/fluoroquinolone-resistant *Enterobacteriaceae*, the overall frequency of carriage of NAL-R bacteria was 36% (38% in Toulouse and 35% in Madrid) and that of CIP-R bacteria was 18% (20% in Toulouse and 15% in Madrid). The multivariate logistic regression analysis indicated that the reason for the dog\'s visit to the veterinary clinic was a predictor of Q/FQ resistance (*p* \< 0.05). Animals brought in for preventive measures were less likely to carry *Enterobacteriaceae* resistant to Q/FQ than those presented for medical treatment (27 vs. 45% for NAL and 12 vs. 25% for CIP). Dog weight was also found to be a predictor of resistance prevalence, but only for NAL (*p* \< 0.01). The population of dogs harboring fecal bacteria resistant to NAL weighed more (median = 14.30 kg) than the population of dogs without resistant bacteria (median = 9.10 kg). A similar trend, but without statistical significance, was apparent for other antibiotics (CTX and CIP).

Characterization of ESBL/AmpC Producers, Genes, Plasmids
--------------------------------------------------------

ESBL/AmpC genes and the plasmids carrying them were identified in 14 cefotaxime-R *Enterobacteriaceae* isolated from the feces ([Table 3](#T3){ref-type="table"}). They included 10 ESBL-producing *E. coli* and 4 AmpC-carrying strains (2 *E. coli*, 1 *P. mirabilis* having acquired AmpC enzyme *and* 1 *C. freundii that carries naturally a chromosomal AmpC*). According to the MLST database, the 12 *E. coli* were associated with 10 different sequence types (STs) of which nine have been previously reported. ESBL-producing *E. coli* presented multiple associated resistances. All strains were resistant to sulfonamides and tetracycline, and some to trimethoprim (5/10), chloramphenicol (4/10), and streptomycin (2/10). ESBL-producers in Madrid were always co-resistant to NAL and CIP whereas those isolated in Toulouse were not, despite the presence of a significant level of Q/FQ resistant strains in the feces. The ESBL phenotype was mostly due to the *bla*~CTX−M−1~ gene (*n* = *6*), whereas the *bla*~CTX−M−15~ gene (*n* = 1 in Toulouse) was rare. The 6 *bla*~CTX−M−1~ genes were systematically carried by the conjugative IncI1/ST3 plasmid subtype that conferred additional resistance to tetracyclines and sulphonamide. The *bla*~CTX−M−1~ IncI1/ST3 plasmid was found in isolates belonging to four different STs (ST6998 (*n* = 2), ST227 (*n* = 1), and ST38 (*n* = 1) in Toulouse and ST602 (*n* = 2) in Madrid). The *bla*~CTX−M−15~ gene was on a conjugative IncI1/ST31 plasmid which did not confer other resistances to its host *strain* which belonged to ST2449. Three *bla*~SHV−12~ genes were also identified, only in Madrid, and were carried by a diversity of conjugative plasmids found in MLST clonally unrelated *E. coli*: *bla*~SHV−12~ IncI1/ST3 plasmid associated with ST453(STC86), *bla*~SHV−12~ IncI1/ST26 with a new ST and *bla*~SHV−12~ IncFII plasmid with ST1594.

###### 

Extended-spectrum cephalosporinase of *Enterobacteriaceae* isolated from feces of healthy dogs in France and Spain and molecular characterization of *bla*~CTX−M~ and *bla*~CMY~ genes and the plasmids carrying them.

  **Strain**   **Site**   **Species**      **Sequence type (ST) ST complex (STC)**   **Phenotype**                           **Non-beta-lactam resistance Pattern**   **Phenotype transferred**   ***bla* gene transferred**   **Co-transferred non-beta-lactam resistance**   **Plasmid replicon type**   **Plasmid sequence type**
  ------------ ---------- ---------------- ----------------------------------------- --------------------------------------- ---------------------------------------- --------------------------- ---------------------------- ----------------------------------------------- --------------------------- ---------------------------
  T22          Toulouse   *E. coli*        ST227 (STC10)                             ESBL                                    SSS TET                                  ESBL                        *bla*~CTX−M−1~               SSS TET                                         IncI1                       ST3
  T39          Toulouse   *E. coli*        ST38 (STC38)                              ESBL                                    SSS TMP TET                              ESBL                        *bla*~CTX−M−1~               SSS TET                                         IncI1                       ST3
  T65          Toulouse   *E. coli*        ST2449                                    ESBL                                    SSS TMP TET                              ESBL                        *bla*~CTX−M−15~              None                                            IncI1                       ST31
  T80          Toulouse   *C. freundii*    New ST                                    AmpC[^\*^](#TN1){ref-type="table-fn"}   TET KAN STR CHL                                                                                                                                                               
  T115         Toulouse   *E. coli*        ST6998                                    ESBL                                    SSS TET                                  ESBL                        *bla*~CTX−M−1~               SSS TET                                         IncI1                       ST3
  T116         Toulouse   *E. coli*        ST6998                                    ESBL                                    SSS TET                                  ESBL                        *bla*~CTX−M−1~               SSS TET                                         IncI1                       ST3
  M9           Madrid     *E. coli*        ST453 (STC86)                             ESBL                                    SSS TMP TET STR CIP NAL                  ESBL                        *bla*~SHV−12~                None                                            IncI1                       ST3
  M40          Madrid     *E. coli*        New ST                                    ESBL                                    TET CIP NAL                              ESBL                        *bla*~SHV−12~                TET                                             IncI1                       ST26
  M49          Madrid     *E. coli*        ST1594                                    ESBL                                    SSS TET STR CHL CIP NAL                  ESBL                        *bla*~SHV−12~                SSS CHL                                         IncFII                      76
  M53          Madrid     *E. coli*        ST12 (STC12)                              AmpC                                    SSS TET STR CHL CIP NAL                  AmpC                        *bla*~CMY−2~                 SSS TET STR CHL                                 IncI1                       ST12
  M76          Madrid     *E. coli*        ST602 (STC446)                            ESBL                                    SSS TMP TET CHL CIP NAL                  ESBL                        *bla*~CTX−M−1~               SSS TET                                         IncI1                       ST3
  M104         Madrid     *E. coli*        ST602 (STC446)                            ESBL                                    SSS TMP TET CHL CIP NAL                  ESBL                        *bla*~CTX−M−1~               SSS TET                                         IncI1                       ST3
  M107         Madrid     *P. mirabilis*   Not applicable                            AmpC[^\*^](#TN1){ref-type="table-fn"}   TET NAL                                                                                                                                                                       
  M110         Madrid     *E. coli*        ST10 (STC10)                              AmpC                                    STR                                      AmpC                        *bla*~CMY−2~                 STR                                             IncI1                       ST12

*SSS, sulfonamides; TMP, trimethoprim; TET, tetracycline; CHL, chloramphenicol; KAN, kanamycin; STR, streptomycin; CIP, ciprofloxacin; NAL, nalidixic acid*.

*strain amplified the bla~CMY~ gene*.

AmpC beta-lactamases were detected in 4 isolates: 1 *C. freundii* isolated from Toulouse dogs and 2 *E. coli*, 1 *P. mirabilis* from Madrid. As CMY-2 is the most common type of AmpC and pAmpC enzymes among *Enterobacteriaceae*, we have focused on the detection of *bla*~*CMY*−2~ *gene*. For the 2 *E. coli*, belonging to ST10 and ST12, the *bla*~CMY−2~ gene was carried by the IncI1/ST12 conjugative plasmid, one carrying only streptomycin resistance while the second was associated with multiple resistances such as sulfonamide, tetracycline, streptomycin and chloramphenicol. The remaining 2, the *bla*~CMY−2~ gene in *P. mirabilis* and the *bla*~CMY−80~ gene in *C. freundii*, were not located on conjugative plasmids.

Discussion {#s4}
==========

The resistance phenotypes investigated in this study are of high clinical relevance in small animal veterinary practice in view of the widespread use of beta-lactams and fluoroquinolones for treating common infections in dogs ([@B4]) and the potential risk of resistance transmission (bacteria or genes) to humans through direct contact ([@B1]).

Prevalence of Resistant *Enterobacteriaceae*
--------------------------------------------

Even if comparison between different studies is difficult due to biases associated with methodological factors, the high prevalences of AMX-R (70%) and CTX-R (18%) *Enterobacteriaceae* were similar to those already reported, over the last 5 years, in healthy dogs in various European countries ([@B5], [@B14], [@B26], [@B27]), but higher than those reported in Denmark, Sweden and the UK ([@B7], [@B15], [@B28]). In our study, the prevalence of AMX-R isolates included *Enterobacteriaceae* species naturally resistant to penicillin like *K. pneumoniae, C. freundii, Enterobacter* and those having acquired such resistance like *E. coli, P. mirabilis*.

Similarly, a high prevalence of NAL-R (35--38%) and CIP-R (15--20%) carriers was detected, as previously reported in Portugal ([@B27]), but higher than that reported in the UK ([@B29]). The use of critically important antimicrobials (3rd and 4th generation cephalosporin and quinolone/fluoroquinolone) is more commonly cited as being prescribed for dogs in Spain, France and Germany than in Sweden and the UK ([@B4]). We therefore believe that the observed high prevalence of cefotaxime (CTX) and Q/FQ resistance in dogs may be associated with the use of critically important antimicrobials for canine treatments.

The prevalence of AMX-R was higher in Toulouse (78%) than in Madrid (63%) but such result is difficult to interpret in light of antibiotic usage data described in the literature for the two countries ([@B4]). Dog weight (Kg) was a risk marker significantly associated with nalidixic acid resistance whereas age was not. This result is difficult to explain but the possible difficulty of precisely administering the recommended dose according to the dog\'s weight might sometimes lead to over-dosing (over-exposure of fecal flora to antibiotics) or under-dosing (which might necessitate a change of antibiotherapy), both situations promoting the development of antibiotic resistance.

The significantly higher prevalence of NAL-R and CIP-R in dogs presented for medical consultation has already been reported ([@B27]) and might be related to the fact that healthy animals have fewer opportunities for contact with antimicrobials. However, the past medical histories of these dogs were not recorded. Exposure to quinolones had previously been indicated as a risk factor for the emergence of resistance to several antibiotics in *E. coli* isolated from dogs ([@B27]) but the involvement of other antimicrobial classes (e.g., tetracyclines, sulfonamides, aminoglycosides), that are frequently used in canine therapy, cannot be excluded. Because no antimicrobial was administered to the dogs during the month prior to sampling, our results are consistent with the hypothesis that the reversibility of resistance in the absence of antimicrobials is a slow process.

It is noteworthy that as almost 20% of the dogs, independently of origin, were CTX-R (ESBL or AmpC) or FQ-R carriers, the owners (including family members) could be at risk of acquiring these resistant bacteria and genes from their dogs ([@B7]) especially if they are carried by conjugative plasmids. FQ resistance was mainly mediated by mutation in chromosomic genes whereas plasmid-mediated FQ resistance (PMQR) determinants only confer low-level resistance to fluoroquinolones. On the 16 CIP-R and 27 NAL-R *Enterobacteriaceae* isolated in our study, we performed the detection for predominant PMQR *qnrA, qnrB, qnrS*, and *aac(6*′*)- Ib-cr* by PCR as described elsewhere ([@B30], [@B31]). No PMQR were detected (data not shown) but we know that among fluoroquinolone non-wild *Enterobacteriaceae*, only 20% carried at least one PMQR determinant ([@B32]).

Characterization of ESBL/AmpC Producers, Genes, and Plasmids
------------------------------------------------------------

Among the ESBL genes identified in *Enterobacteriaceae* isolated from different dogs in the two countries, the *bla*~CTX−M−1~ gene was exclusively located on the specific conjugative IncI1/ST3 plasmid. Although this study is the first to identify *bla*~CTX−M−1~ on IncI1/ST3 plasmid in Spain, such a combination has recently been reported in France in healthy urban dogs ([@B5]), in both diseased and healthy humans ([@B33]) but also in food-producing animals and the environment ([@B22], [@B34]). The *bla*~CTX−M−1~ on IncI1/ST3 plasmid was detected in four different *E. coli* ST, including ST38 and ST602 which have frequently been identified in different situations (human pathogens or not, livestock, environment) but are only rarely found in dogs. The *E. coli* ST38 and ST602 lineages carrying *bla*~CTX−M−1~ on IncI1/ST3 plasmids have previously been reported in food-producing animals in Portugal ([@B35]) and healthy dogs ([@B36]) in Tunisia, respectively. The diversity of the analyzed strains (date and place of isolation) and the diversity of the *E. coli* ST, in contrast to the homogeneity of the *bla*~CTX−M−1~ plasmid type, confirm the specific capability of the *bla*~CTX−M−1~-carrying IncI1/ST3 plasmid to disseminate through unrelated bacterial strains.

In our study, one *bla*~CTX−M−15~/IncI1/ST31 conjugative plasmid, carrying an additional *bla*~TEM−1~ gene without additional resistance, was identified in a French isolate. Such a plasmid has already been detected in *E.coli* and *Shigella sonnei* clinical isolates from cattle and humans in different European countries ([@B37], [@B38]). This plasmid was found in *E. coli* ST2449 which has been reported once for a human pathogen in Europe and twice on the American continent for animal pathogens (<http://enterobase.warwick.ac.uk/species/ecoli/search_strains>).

Three *bla*~SHV−12~ genes were identified only in Spain and were carried by three different conjugative plasmids: the *bla*~SHV−12~ IncI1/ST3 plasmid previously reported in 2 *E. coli* of poultry origin in Italy ([@B39]), the *bla*~SHV−12~ IncI1/ST26 plasmid previously identified in *E. coli* of human origin in Italy ([@B39]), from food animals and products in Portugal ([@B35]) and the *bla*~SHV−12~ F76:A-:B- FII plasmid not yet described. In addition, SHV-12-carrying plasmids were located in three different genetic lineage strains. Among them, a new ST and 2 other STs (ST453, ST1594) that have occasionally been detected in livestock and poultry on different continents as well as in the environment and humans for ST453 ([@B40], [@B41]). The ability of *bla*~SHV−12~ genes to combine with different plasmids allows the enzymes to attain diverse niches worldwide, as previously demonstrated ([@B42]). Prevalence of the *bla*~SHV−12~ gene seemed higher in Spain but the number of cefotaxime-R isolates in France was too small to draw a conclusion.

Three AmpC were detected among the eight cefotaxime-R *Enterobacteriaceae* in Spain but only one in France. The *bla*~CMY−2~ on IncI1/ST12 plasmid was the only conjugative plasmid-encoded p*Amp*C gene that we detected in two different *E. coli* lineages (ST10 and ST12). The *E. coli* ST10 and ST12 have repeatedly been isolated from various reservoirs i.e., healthy or diseased animals including dogs, humans and the environment ([@B40]). Previous studies support the hypothesis that plasmids play the major role in the transmission of *bla*~CMY−2~ between reservoirs. The widespread distribution of *bla*~CMY−2~-carrying IncI1/ST12 plasmid has been reported among various *E. coli* STs from human patients, livestock animals, food, environment, and also from healthy dogs in Tunisia ([@B17], [@B35], [@B36], [@B41], [@B43]). However, to our knowledge, this is the first time that the *bla*~CMY−2~ IncI1/ST12 plasmid has been identified in healthy dogs in Europe although it was recently identified in a single clinical isolate associated with another ST in Denmark ([@B17]). Until now, the *bla*~CMY−2~ on IncI1/ST2 plasmid was the only one reported in healthy dogs in Europe ([@B5], [@B11], [@B17]). *E. coli* ST10 harboring *bla*~CMY−2~ on the IncI1/ST12 plasmid seems to circulate in European broiler production ([@B17]). In addition to food animals, which are often proposed as possible reservoirs for *bla*~CMY−2~ in humans through the spread of specific plasmids, our results also raise questions about the possible contribution, to this burden in Europe, of *bla*~CMY−2~-carrying IncI1/ST12 plasmid from companion animals.

The third AmpC-carrying isolate in Spain was a CMY-2-producing *Proteus mirabilis* in which mobilization of the *bla*~CMY−2~ gene does not involve a plasmid. Hybridization experiments are needed to confirm the chromosomal location of this *bla*~CMY−2~ gene. In France, a single CMY-80-producing *Citrobacter freundii* was found in canine feces and the bla~CMY~ variant gene was not carried by a conjugative plasmid. Such a *bla*~CMY~ variant was only found in *C. freundii* isolated from human urine samples in Spain (GenBank Accession Number JQ733577).

Overall, a diversity of *bla*~ESBL/pAmpC~ genes were found but the *bla*~CTX−M−15~ which is highly predominant in the ESBL-producers in human and dog pathogens seems minor in the commensal digestive flora ([@B44]--[@B47]). In the other hand, *bla*~CTX−M−1~ and *bla*~SHV−12~ have recently emerged in dog pathogens ([@B45]). ESBL/AmpC genes were found in different clonal lineages of *E. coli* but not in the most prevalent ST in human (ST131, ST648) and dog (ST410) pathogens. However, some successful ESBL/pAmpC plasmid lineages have been described in human and dog pathogens.

In our study, most of the ESBL/AmpC strain isolated from Madrid presented the broadest multiresistance pattern, showing co-resistance to ESC and FQ. Similarly, such co-resistance in *E. coli* from food or food-producing animals in Europe was shown to occur at the highest frequency in Spain ([@B48]). We performed the detection for predominant PMQR *qnrA, qnrB, qnrS*, and *aac(6\')- Ib-cr* by PCR as described elsewhere on ESBL/AmpC strain but no PMQR were detected except a qnrA gene in the AmpC-producer C. freundii (data not shown). In our study, the low prevalence of PMQR contrast with the high prevalence previously described in dog pathogens ([@B32], [@B44], [@B49]). Anyway, multiresistance to different classes of antibiotic used in veterinary medicine, conferred by conjugative plasmids and/or by the host strains, may increase the potential risk of co-selection, maintenance, transmission, and propagation of the multidrug-resistant *E. coli* isolates and/or multidrug-resistant plasmids in digestive tract. Moreover, despite the few strains studied here, and in addition to the greater multiresistance reported in Spain, our results suggest that the diversity of ESBL/pAmpC genes and plasmids is greater in Spain than in France. This may be due to a geographical factor, differences in the use of antibiotics in dogs or differences in the distribution of ESBL/Ampc strains and plasmids in the environment of dogs (humans, water, and food). The sharing of ESBL/pAmpC-carrying plasmids between healthy dogs and humans is of particular concern.

In conclusion, our study reveals a high prevalence of resistance to fluoroquinolones (18%) and extended-spectrum-cephalosporins (18%) in feces from dogs in Toulouse and Madrid. The state of health of the animals is a risk factor for quinolone-resistance carriage, probably related to previous treatments. In unrelated dogs in Spain and/or France, the spread of extended-spectrum-cephalosporinases can be due to successful combination of particular ESBL/pAmpC genes and specific plasmid ST, as for *bla*~CTX−M−1~/IncI1/ST3 and *bla*~CMY−2~/IncI1/ST12. On the contrary, the *bla*~SHV−12~ gene combines with different plasmid lineages. Such highly conjugative plasmids have previously been described in healthy or pathogenic *E. coli* isolates of human, animal and food origin. They are located in different *E. coli* ST, and some are increasingly being identified in various known reservoirs. Considering the prevalence of resistance to fluoroquinolones and extended-spectrum-cephalosporinases (notably the large reservoir of CTX-M-1 and CMY-2 producers in dogs) there is a serious and plausible risk of future acquisition of CTX-M-1 and CMY-2 plasmids by their owners.
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